ES2912267T3 - Métodos de tratamiento de enfermedades asociadas a S. aureus - Google Patents
Métodos de tratamiento de enfermedades asociadas a S. aureus Download PDFInfo
- Publication number
- ES2912267T3 ES2912267T3 ES13853844T ES13853844T ES2912267T3 ES 2912267 T3 ES2912267 T3 ES 2912267T3 ES 13853844 T ES13853844 T ES 13853844T ES 13853844 T ES13853844 T ES 13853844T ES 2912267 T3 ES2912267 T3 ES 2912267T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- aureus
- amino acid
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 27
- 201000010099 disease Diseases 0.000 title description 23
- 238000011282 treatment Methods 0.000 title description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 78
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 34
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 26
- 230000001147 anti-toxic effect Effects 0.000 claims description 45
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 230000027455 binding Effects 0.000 description 111
- 239000012634 fragment Substances 0.000 description 82
- 239000000427 antigen Substances 0.000 description 81
- 108091007433 antigens Proteins 0.000 description 81
- 102000036639 antigens Human genes 0.000 description 81
- 230000001580 bacterial effect Effects 0.000 description 44
- 208000015181 infectious disease Diseases 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 34
- 206010040047 Sepsis Diseases 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 125000000539 amino acid group Chemical group 0.000 description 29
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 101710182532 Toxin a Proteins 0.000 description 21
- 239000002776 alpha toxin Substances 0.000 description 21
- 101710092462 Alpha-hemolysin Proteins 0.000 description 20
- 101710197219 Alpha-toxin Proteins 0.000 description 20
- 101710124951 Phospholipase C Proteins 0.000 description 20
- 239000012636 effector Substances 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 20
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 19
- 229960004397 cyclophosphamide Drugs 0.000 description 19
- 210000002216 heart Anatomy 0.000 description 19
- 108010087819 Fc receptors Proteins 0.000 description 18
- 102000009109 Fc receptors Human genes 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 210000000440 neutrophil Anatomy 0.000 description 14
- 238000011321 prophylaxis Methods 0.000 description 14
- 230000004520 agglutination Effects 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000009424 thromboembolic effect Effects 0.000 description 12
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 9
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 208000004235 neutropenia Diseases 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 7
- 238000004820 blood count Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 6
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 208000031729 Bacteremia Diseases 0.000 description 5
- 108010073807 IgG Receptors Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101000800763 Naja pallida Short neurotoxin 1 Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 102000036664 ADAM10 Human genes 0.000 description 3
- 108091007504 ADAM10 Proteins 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 238000012754 cardiac puncture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000005119 Necrotizing Pneumonia Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010051017 Staphylococcal bacteraemia Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- -1 but not limited to Proteins 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010062119 complement 1q receptor Proteins 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2912267T3 true ES2912267T3 (es) | 2022-05-25 |
Family
ID=50685101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13853844T Active ES2912267T3 (es) | 2012-11-06 | 2013-11-05 | Métodos de tratamiento de enfermedades asociadas a S. aureus |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (OSRAM) |
| EP (1) | EP2928490B1 (OSRAM) |
| JP (2) | JP6506172B2 (OSRAM) |
| KR (3) | KR20150092738A (OSRAM) |
| CN (2) | CN112316135A (OSRAM) |
| AU (2) | AU2013341421A1 (OSRAM) |
| BR (1) | BR112015010126B1 (OSRAM) |
| CA (1) | CA2890385C (OSRAM) |
| ES (1) | ES2912267T3 (OSRAM) |
| MX (1) | MX367082B (OSRAM) |
| RU (1) | RU2661406C2 (OSRAM) |
| SG (2) | SG10201703677VA (OSRAM) |
| WO (1) | WO2014074470A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2708977C2 (ru) | 2011-06-10 | 2019-12-12 | МЕДИММЬЮН, ЭлЭлСи | Молекулы, связывающиеся с psl pseudomonas, и пути их применения |
| BR112014011028B1 (pt) | 2011-11-07 | 2021-03-02 | Medimmune, Llc | anticorpo biespecífico, composição, e, uso da composição |
| MX367082B (es) * | 2012-11-06 | 2019-08-05 | Medimmune Llc | Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. |
| EP2917360B1 (en) * | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| CA3107463A1 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| BR112021006704A2 (pt) | 2018-10-09 | 2021-08-10 | Medimmune, Llc | anticorpos dirigidos contra leucotoxinas de staphylococcus aureus |
| TW202035443A (zh) | 2018-10-09 | 2020-10-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌抗體的組合 |
| JP7682795B2 (ja) | 2019-03-13 | 2025-05-26 | メディミューン，エルエルシー | コロニー形成患者における黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症の低減 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007145689A1 (en) | 2006-06-12 | 2007-12-21 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| EP2453881A2 (en) * | 2009-07-16 | 2012-05-23 | Georgia Health Sciences University Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| HRP20182017T4 (hr) | 2011-02-08 | 2021-08-20 | Medimmune, Llc | Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe |
| JP2014507142A (ja) * | 2011-02-08 | 2014-03-27 | インテグレイテッド バイオセラピューティクス，インコーポレイテッド | α溶血素オリゴペプチドを含む免疫原性組成物 |
| MX367082B (es) * | 2012-11-06 | 2019-08-05 | Medimmune Llc | Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. |
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 MX MX2015005481A patent/MX367082B/es active IP Right Grant
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/ko not_active Ceased
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/ko active Active
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/ko not_active Ceased
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/pt active IP Right Grant
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en not_active Ceased
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/ru active
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
- 2013-11-05 ES ES13853844T patent/ES2912267T3/es active Active
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/ja active Active
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/zh active Pending
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/zh active Pending
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/ja active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2912267T3 (es) | Métodos de tratamiento de enfermedades asociadas a S. aureus | |
| JP6694269B2 (ja) | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 | |
| CA2866943A1 (en) | Treatment of multiple sclerosis with anti-cd19 antibody | |
| JP2022512647A (ja) | 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ | |
| HK1215173B (en) | Methods of treating s. aureus-associated diseases | |
| US20240109961A1 (en) | Treatment of chronic prurigo | |
| US20240392005A1 (en) | Pd-1/tigit binding proteins for cancer treatment | |
| TW202511292A (zh) | 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白 | |
| WO2025250726A1 (en) | Anti-kit antibody dosing and methods | |
| CN117120089A (zh) | 慢性痒疹的治疗 | |
| HK40025295A (en) | Antibodies to s. aureus surface determinants | |
| HK1215452B (zh) | 金黃色葡萄球菌表面決定簇的抗體 |